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The Effect of Methotrimeprazine on
Arterial Blood Gases in Human Volunteers
Elemer K. Zsigmond, MD, and Kathleen Flynn, BS
Since methotrimeprazine proved to be both an effective tranquilizer and analgesic, its
effect in a tranquilizing dose of 0.15 mg/kg on the arterial blood gases was determined in
human volunteers. Because of the known potentiating effect of some phenothiazines on
the narcotic-analgesic induced respiratory depression and analgesia, the effect of meth-
otrimeprazine on the meperidine-induced respiratory depression was also studied. Be-
fore, and at five minute intervals after the administration of the test drugs, Pa02, PaCO2
and pH were determined by a Radiometer Copenhagen Blood Gas Analyzer (Radiometer
Copenhagen, 72 Endruvej, Denmark) through a Riley-needle. Continuous EGG lead II
tracings were taken during the experiment. No significant decrease in PaO2 or increase
in PaCO2 (P <0.01) was observed in 6 healthy volunteers (mean age = 25 yrs) after 0.15
mg/kg iv. methotrimeprazine. In 19 volunteers (mean age = 32 yrs), the intravenous
infusion of 1.5 mg/kg meperidine caused significant decrease in Pa02 and increase in
PaCO2 five minutes after its administration. The combined administration of both drugs
to 6 volunteers (mean age = 23 yr) caused initially the same decrease in Pa02 as after
meperidine alone with subsequent increase in PaO2 over normal levels, however, the
PaCO2 significantly increased both as compared to baseline values and as compared
with meperidine alone. The pH reductions after the combination of both drugs were
greater than after meperidine alone, which in combination with the PaCO2 values con-
firms the potentiation of meperidine-induced respiratory depression by methotrimepra-
zine. The results indicate the methotrimeprazine alone causes no significant respiratory
depression, but it potentiates the respiratory depression caused by meperidine.
T ranquilizers are commonly used to reduce anxi-
ety and restlessness in psychiatric, critically ill,
cardiac, and surgical patients and for the so-called
ataract analgesia, a new anesthetic technique based
on the combined use of tranquilizers and narcotic
analgesics. Although the use of methotrimeprazine
declined to a great extent in the past two decades
since our original study was conducted, there is a
revival of interest in its use not only for analgesia
during surgical anesthesia but also in its use in the
management of cancer pain.15 Therefore, it is es-
sential to know if and to what extent a particular
tranquilizer depresses respiration.
Methotrimeprazine is both an effective tranquil-
izer6 and a potent analgesic agent7 and has a unique
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place in our armamentarium of drugs. Ample evi-
dence has been presented for its tranquilizing, anti-
histaminic, anti-serotonin and antiemetic effect in
the literature.6#{176} Double-blind studies on its analge-
sic effect for the relief of postoperative pain by Keats
and associates11 and Lasagna and DeKornfeld12 re-
vealed that 10 mg/70 kg of methotrimeprazine
equals the effect of 10 mg/70 kg morphine. A dou-
ble-blind study on the efficacy of 0.2, 0.15 and 0.10
mg/kg i.v. methotrimeprazine conducted prior to its
evaluation of the respiratory effects* demonstrated
that 0.1 mg/kg adequately relieved preoperative
anxiety without adverse circulatory and respiratory
effects in 120 surgical patients. The lack of respira-
tory depressant effect of methotrimeprazine was
shown earlier by the studies of Pearson and De-
Kornfeld,13 who could not find a significant shift in
the GO2 ventilation response curves in six volun-
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TABLE I
The Effect of Premedlcatlons on the Pa02 in Healthy Human Volunteers
Mean ± S.D. Pa02
Drugs N 0 mm 5 mm 10 mm 20 mm 30 mm 60 mm
Methotrimeprazine
0.15 mg/kg 6 88.1 ± 6.0 93.1 ± 9.3 96.7 ± 11.9 96.8 ± 6.2* 99.8 ± 6.3** 98.0 ± 79*
Meperidine 1.5




mg/kg 6 87.2 ± 10.3 80.2 ± 5.7 84.0 ± 6.7 86.5 ± 4.3 91.0 ± 2.8ttt 95.2 ± 4.8tft
* P <0.05 as compared to 0 mm value. t P < 0.05 as compared to the meperidmne group.
P < 0.01 as compared to 0 mm value. tt P < 0.01 as compared to the meperidmne group.
P < 0.001 as compared toO mm value. fit P < 0.001 as compared to the meperidine group.
Based on these findings, we believed that metho-
trimeprazine may be a potential single agent for the
induction and maintenance of neuroleptanalgesia,
thereby replacing the mixture of tranquilizers and
analgesics. Before the initiation of a clinical trial for
neuroleptanalgesia, further studies on its respiratory
and circulatory effect in human volunteers were in-
dicated. Since it may be also used in combination
with other analgesic agents before, during or after
anesthesia, studies were planned on its effect on the
narcotic-caused respiratory depression. This report
encompasses the results of blood gas studies in
healthy volunteers after methotrimeprazine, me-
peridine and their combinations.
METHODS
Thirty one healthy adult volunteers of both sexes
were studied. The criteria for the selection were: 1)
individuals with no systemic disease, 2) no pregnant
women, 3) no minors, 4) no individuals habituated to
or on drugs.
Six volunteers with a mean age of 25 years (21-26)
received 0.15 mg/kg methotrimeprazine; nineteen
volunteers with a mean age of 32 years (19-52) were
administered 1.5 mg/kg of meperidine; six volun-
teers with a mean age of 23 years (20-26) were given
a combination of 0.15 mg/kg methotrimeprazine
with 1.5 mg/kg meperidine.
After admission to the Anesthesia Research Unit,
a 20 ga. Riley needle was inserted into the brachial
artery contralateral to the predominant arm. After a
20 minute rest period, two baseline blood gas sam-
ples were taken. If the two baseline values were
within 5%, the study was begun. All the studies
were carried out in the supine position.
The Pa02, PaGO2, pH and base excess were deter-
mined on a Radiometer Copenhagen Blood Gas An-
alyzer according to the equilibration technique of
Astrup at 5, 10, 20, 30 and 60 minutes following the
intravenous administration of the test medications.
The test medications were always administered in-
travenously in 50 ml physiologic saline solution in-
fused by a Harvard-pump over a 2 minute period.
Lead II EGG and direct arterial blood pressure via




Methotrimeprazine caused no significant decrease
(P < 0.05) in PaO2 at any time after its administra-
tion, but rather a statistically significant increase
after 20 mm. in PaO2, which peaked at 30 minutes
(Table I, Fig. 1). No significant (P < 0.05) elevation in
PaCO2 was observed at any time after methotrimep-
razine (Table II, Fig. 1). pH and base excess also re-
mained unchanged (Table III). These findings indi-
cate that methotrimeprazine causes no significant
detectable respiratory depression by blood gas deter-
minations.
Meperidine alone caused a significant reduction in
Pa02 (Table I), and a significant increase (P < 0.05) in
PaGO2 only at 5 mm. (Table II) but no reduction in











The combination of methotrimeprazine with me-
peridine resulted initially in no greater reduction in
PaO2 than meperidine alone at 5 minutes (Table I,
Fig. 1). At 30 minutes and 60 minutes, even signifi-
cant increases in PaO2 (P < 0.001) were observed in
the group of patients receiving methotrimeprazine
in combination with meperidine as compared to
those receiving meperidine alone (Table I). These
changes, however, were not significant when com-
pared with baseline. The combination of methotri-
meprazine with meperidine caused significant in-
creases in PaGO2 at all times as compared to the
baseline (Table II). Furthermore, significantly higher
PaGO2 values (at P < 0.001 and 0.05) were found in
the group of volunteers receiving the combination as
compared to those receiving meperidine alone at 20
and 30 minutes (Table II). Since the pH reductions
were identical to the PaGO2 increases following the
drug combination, methotrimeprazine markedly in-
creased the respiratory depression caused by me-
peridine alone (Table III, Fig. 1).
DISCUSSION
This is the first report on the effect of methotrimep-
razine on arterial blood gases in healthy volunteers
and on its possible potentiating effect on the meper-
idine induced respiratory depression. Our findings
corroborate some earlier reports on the potentiation
of the narcotic-induced respiratory depression by
phenothiazines, especially after their intravenous
injection in rapid sequence.1415 The excessive seda-
tion, after the combination of meperidine and meth-
otrimeprazmne, which resulted in most instances in
deep sleep, might have also contributed to the ele-
Figure. Arterial blood gas changes following intravenous adminis-
tration of 0.15 mg/kg methotrimeprazine, 1.5 mg/kg meperidine
and their combination. Upper lines represent Pa02 and lower lines
represent PaCO2. The individual symbols represent means
± standard deviation from the mean (±S.D.). For statistical signifi-
cance, we refer the reader to Tables 1-111, since the results with the
drug combination was compared not only to the baseline but also
to the meperidine group. Crowding of the presentation of statisti-
cal significance was thereby avoided on the Figure.
vation of arterial carbon dioxide tension. However,
the increase in PaGO2 cannot be completely ex-
plained by the sleep alone, since its magnitude ex-
ceeded that reported in natural sleep.1617
However, the significant differences between the
pH changes that followed the administration of me-
peridine in combination with methotrimeprazine ei-
TABLE II
The Effect of Premedlcations on the PaCO2 in Healthy Human Volunteers
Mean ± S.D. PaCO2
Drugs N 0 mln 5 mln 10 mln 20 mln 30 mln 60 mm
Methotrimeprazine
0.15 mg/kg 6 33.5 ± 2.3 30.9 ± 4.8 31.1 ± 2.0 33.6 ± 3.1 31.7 ± 2.7 35.2 ± 5.4
Meperidine 1.5




mg/kg 6 35.8 ± 3.5 40.0 ± 1.7* 41.7 ± 4.2* 43.7 ± 1.7***ftt 42.3 ± 2.8**t 41.8 ± 2.76*
* P < 0.05 as compared to 0 mm value. f P < 0.05 as compared to the mepermdmne group.
“ P < 0.01 as compared to 0 mmn value. ti P < 0.01 as compared to the mepermdmne group.
“ P < 0.001 as compared toO mm value. ttf P < 0.001 as compared to the mepermdmne group.
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TABLE Ill
The Effect of Premedications on the pH Values in Healthy Volunteers
Mean ± S.D. pH
Drugs N 0 mm 5 mm 10 mm 20 mm 30 mm 60 mm
Methotrimeprazine
0.15 mg/kg 6 7.42 ± 0.01
Meperidine 1.5








7.42 ± 0.01 7.42 ± 0.02 7.42 ± 0.02
7.38 ± 0.03 7.38 ± 0.02 7.38 ± 0.02




#{149}P < 0.05 as compared to 0 mm value.
P < 0.01 as compared to 0 mmn value.
P < 0.001 as compared to 0 mmn value.
t P < 0.05 as compared to the mepermdmne group.
tt P < 0.01 as compared to the mepermdine group.
ttt P < 0.001 as compared to the meperidmne group.
ther as compared with the baseline or to those
caused by meperidine alone at the P < 0.01 and P
< 0.001 probability level indicate a marked poten-
tiation of the respiratory depression by methotri-
meprazine. We must emphasize that in clinical
practice such large intravenous doses of meperidine
and methotrimeprazine, especially in combination,
ought to be avoided, as this combination may result
in profound sleep lasting for several hours accompa-
nied with marked respiratory acidosis.
The findings indicate that 0.15 mg/kg i.v. metho-
trimeprazine alone, which is sufficient dose for re-
lief of either pain or anxiety, causes no significant
changes in PaO2, PaGO2, pH or base excess in
healthy human volunteers. Subsequent studies5’8’9
corroborated our finding on the lack of respiratory
depression caused by methotrimeprazine. Petts and
Pleuvry’8 observed a lack of significant displace-
ment of the ventilatory response curve to CO2 to the
right following 2.5 mg i.m. methotrimeprazine in 10
healthy volunteers, whereas morphine 5 mg i.m.
caused a significant shift to the right in a double-
blind crossover study using the methods of Redpath
and Pleuvry.2#{176} In their study, however, contrary to
our findings, methotrimeprazine caused no further
ventilatory depression when combined with mor-
phine in healthy volunteers than morphine alone.
This finding may be explained by the suboptimal
doses of both drugs used in their study that are not
equipotent to the doses used in our study. Moreover,
the authors believed that the accuracy and sensitiv-
ity of the trial should have been increased by using a
greater number of volunteers and by administering
the drugs on a mg/kg basis rather than in a fixed mg
dose regardless of weight. In contrast, optimal, ef-
fective analgesic doses of 1.5 mg/kg meperidine i.v.
caused a significant reduction in Pa02 at 5 and 10
minute in both healthy volunteers and lung disease
patients, that may cause severe decrease in oxygen
saturation in patients with chronic obstructive lung
disease as we previously published in this jour-
nal.2122 Therefore, methotrimeprazine has prefer-
ence to meperidine as an analgesic agent, when used
alone in patients in whom respiratory depression
should be avoided.
Double-blind studies by Radnay et al.19 provided
new evidence for the advantages of methotrimepra-
zine over meperidine in neuroleptanalgesia. They
observed in their double-blind study in anesthetized
patients, supplemented by either of these drugs as an
analgesic component, that respiratory parameters
were little affected by methotrimeprazine while
ventilation was markedly depressed by meperidine.
Although in our study methotrimeprazine in combi-
nation with meperidine caused no greater reduction
in PaO2 than meperidine alone, the significant ele-
vation in PaGO2 and parallel reduction in pH ob-
served for 60 minutes after the combination indi-
cates either an additive or potentiating of the effect
of methotrimeprazine on respiratory depression
caused by meperidine. Thus the combination of
methotrimeprazine with meperidine should be used
cautiously in clinical practice in view of the evi-
dence obtained from our study.
In conclusion: If respiratory depression is to be
avoided, methotrimeprazine is safer than meperi-
dine, especially in patients with already impaired
ventilation.
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